UTILISATION DES PROTÉINES PD-1 ET CD38 COMME MARQUEURS D'UNE PATHOLOGIE AUTO-IMMUNE ACTIVE
European patent · EP4212877 · In force
Register entry
- Publication number
- EP4212877
- Application number
- EP23156126
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- May 19, 2020
- Published
- Jul 19, 2023
- Granted
- Mar 19, 2025
- Protection ends at the latest
- May 18, 2040
- Next annual fee due
- May 31, 2026
- IPC classes
- G01N 33/564 (2006.01)
- Priority
- FR 1905358 22.05.2019
- Divided from
- EP20726132
- Filing language
- French
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jan 28, 2026
Change
Published in Swissreg on 28.01.2026
- Jun 11, 2025
Agent entered
- Representative
- Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex
Published in Swissreg on 11.06.2025
- Jun 1, 2025
Change
Published in Swissreg on 01.06.2025
- Mar 19, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 19.03.2025
Parties
Holder
Inventor
RENAND, Amédée
44980 SAINTE-LUCE-SUR-LOIRE, FR
CONCHON, Sophie
44300 NANTES, FR
GOURNAY, Jérôme
44100 NANTES, FR
AUBLE, Hélène
44000 NANTES, FR
HABES, Sarah
44200 NANTES, FR
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.